Research-use catalogue combines prefilled formats, clear product specifications and supporting documentation, with free delivery across the United Kingdom.

United Kingdom, 5th Nov 2026 – Maylene is putting the spotlight on its best-selling research peptide range, giving laboratory buyers access to an online catalogue backed by UK dispatch, clearly displayed pricing and available product documentation.

The Maylene platform brings together research peptides, individual compound listings and educational resources in one place. Visitors can explore available products, compare labelled strengths and review format and pack information before placing an order.

With free UK-wide delivery, Maylene offers a convenient purchasing option for laboratory buyers who value accessible product information and straightforward ordering. Its catalogue includes individual compounds, blends and bundles, allowing customers to browse different options according to their research requirements.

Featured Compounds Across the Maylene Range

Maylene’s featured selection includes BPC-157, GHK-Cu, retatrutide and compound blends, giving laboratory buyers a range of research-use options to explore. Each listing clearly presents the product name, labelled content, format and price, making it easier to compare specifications and review available supporting documentation before ordering.

This presentation gives customers a practical basis for comparison. Rather than relying on a product name alone, visitors can review the stated strength, check the selected pack and examine any supporting records available for that product.

For buyers exploring multiple options, dedicated collections make it easier to navigate the catalogue and move between individual listings. Product bundles are also presented separately, helping visitors distinguish a single item from a combined purchase.

Prefilled Research Formats in One Collection

The Maylene peptide pen collection brings together prefilled single-compound and blend products. Listings identify labelled content and pack quantities so laboratory buyers can compare available formats with greater clarity.

The distinction between individual content and total pack content is particularly useful when reviewing multipacks. A pack containing two pens has a different specification from a single pen carrying the same combined total. Maylene’s product information allows visitors to check those details before purchasing.

Blend listings also provide composition information, giving buyers a way to review the individual compounds within a product rather than relying only on its combined labelled strength.

All products in the collection are supplied for laboratory and research purposes only.

Product Documentation Available for Review

Alongside its catalogue, Maylene provides access to published laboratory reports where available. Customers can review these records and check whether the documentation corresponds to the product and strength they intend to purchase.

Maylene explains that published reports relate to the samples tested. They do not verify every batch in stock, and report coverage is not available for every product. Buyers should therefore check the documentation relevant to their exact item and contact the team where further clarification is needed.

Making these distinctions visible gives customers a more useful basis for evaluating product information. Labelled specifications, published records and batch details each serve a different purpose and should be considered together.

Free UK Delivery and Direct Support

Maylene offers free delivery across the United Kingdom, with products dispatched from the UK and tracking information provided after dispatch. International shipping is also available, with delivery details presented on the website.

Customers can review ordering information before completing a purchase, including their selected product, pack quantity and total. For questions about available documentation, product specifications or the ordering process, Maylene provides direct support through its listed contact channels.

This combination of UK fulfilment and accessible support gives laboratory buyers a clear route from browsing the catalogue to resolving product-specific enquiries.

Research Resources Beyond the Catalogue

Maylene’s website also features educational guides and compound information, providing additional context for visitors exploring its range. These resources sit alongside the commercial catalogue, allowing buyers to review background information while checking individual product specifications.

The platform brings together catalogue navigation, research reading and available documentation without changing the products’ stated purpose. Educational material does not establish suitability for human use or replace the assessments required for a laboratory’s own work.

Maylene invites laboratory buyers to explore its featured range, compare available formats and review the relevant product information before ordering.

About Maylene

Maylene supplies research-use products dispatched from the United Kingdom. Its online catalogue includes individual compounds, prefilled research pens, blends and bundles, supported by educational resources and available laboratory documentation. The company offers free UK delivery and international shipping options.

Research-Use Notice

All products sold by Maylene are intended solely for laboratory and research purposes. They are not intended for human or veterinary use, consumption or application. Product descriptions and educational resources do not constitute medical advice.

Media Contact

Organization: Maylene

Contact Person: Sam Aquino

Website: https://www.maylene.uk/

Email: Send Email

Country: United Kingdom

Release id: 50483

View source version on King Newswire:
Maylene Showcases Its Best-Selling Research Peptides with UK-Wide Delivery

From a land shaped by ancient civilisations, Iraqi researcher Mayes Ali Hadi Al-Hassany brings together pharmaceutical science, project management and technology. She has a clear goal for investors to get behind: building factories in Iraq that make medicines patients can trust and supply them to markets across the region.

Iraq, 5th Nov 2026 – Together We Build Iraq Mayes Ali Hadi Al-Hassany’s Journey from the Laboratory to a Vision for Iraqi-Made Medicines – Together, we build Iraq. Imagine a pharmacist in Amman or Dubai reaching for a box marked “Made in Iraq.” Behind that box are researchers who developed its formulation, technicians who mastered its production, and a laboratory that verified its quality before it left the factory. This is the scene Mayes Ali Hadi Al-Hassany wants to see become part of Iraq’s future.

Returning to the Classroom

Mayes Al-hassany began her career in pharmacy and went on to pursue research in pharmaceutical science and manufacturing. After gaining experience in the field, she stepped away from pharmacy practice for a time and returned to the classroom to study project management. She wanted to learn how to secure funding for a scientific idea, build the team to carry it out, and use promising laboratory results to make a case for manufacturing to investors.

She attended several international conferences, kept up with developments in Western pharmacy markets, and studied the business models of retailers such as Australia’s Chemist Warehouse, Britain’s Boots and Watsons. What caught her attention was the work behind the shelves. Even before a factory buys its first piece of equipment, demand, product availability and distribution can help determine which medicines are worth making and in what quantities.

From Pharmaceutical Research to the Factory Floor

Mayes Al-hassany completed a series of studies in pharmaceutical science and manufacturing and published her work internationally. Her research included developing a formulation for extended-release metformin tablets and comparing its drug-release profile with that of a reference product. She also studied the stability of amlodipine tablets under hot and humid conditions to understand how formulation and packaging affect the quality of the medicine during storage.

She discussed her work with academics and researchers from universities and research centres in several countries. Some of those who reviewed her studies and discussed them with her expressed admiration for her work. They saw her ability to connect laboratory questions with manufacturing challenges as a sign of what she could contribute to pharmaceutical science in the years ahead.

That connection shapes her vision for Iraqi manufacturing. She wants an Iraqi factory to begin with a carefully chosen product, a team that knows how to maintain its quality, and a system that can trace every batch. Once the factory demonstrates consistent quality and reliable supply, it can pursue registration and distribution in neighbouring markets in line with local requirements.

A Call to Iraqi Investors

Mayes Al-hassany’s message to investors is clear. Invest in pharmaceutical factories in Iraq and in the people who will run and improve them. A single production line backed by a sound feasibility study can give Iraqi researchers a place to put their knowledge to work at home, young technicians a chance to gain industrial experience, and patients access to locally made medicines they can trust.

For Mayes Al-hassany, pride in Iraq’s heritage finds expression in the path she has chosen. She wants to put her knowledge to work for others and bring the questions she learned to ask in the laboratory to the factory floor. When a box of Iraqi-made medicine reaches a pharmacy beyond the country’s borders, the achievement worth celebrating will be the work behind it: the people who turned scientific knowledge into a medicine someone could depend on.

Media Contact

Organization: HQearth

Contact Person: Mayes Ali Alhassany

Website: https://www.hqearth.org/

Email: Send Email

Country: Iraq

Release id: 50485

View source version on King Newswire:
Together We Build Iraq Mayes Ali Hadi Al-Hassany’s Journey from the Laboratory to a Vision for Iraqi-Made Medicines

Seoul, South Korea, November 5th, 2026, Chainwire

With phased rollout targeted for the first half of 2027, the service is expected to connect LINE FRIENDS’ online and offline commerce with the Web3 ecosystem, offering customers in Korea and abroad an additional payment option for purchasing physical products with minicoin

Digital IP entertainment company IPX (formerly LINE FRIENDS) plans to introduce a payment service using ‘minicoin’ at LINE FRIENDS online and offline stores. The service is intended to make digital asset payments a seamless extension of the fan experience, linking fans’ engagement with character IP to the point of purchase and connecting IPX’s online and offline commerce with a Web3-based digital ecosystem.

For more than a decade, IPX has brought its character IPs to life through products, content, and pop-ups, extending these experiences across online and offline channels worldwide. Building on its expertise in IP and retail, the introduction of this service presents a new digital IP commerce model that integrates digital asset payment technology into IP merchandise purchases.

Minicoin is a utility coin developed and issued by Mini Labs under an official license granted by IPX to use its globally popular ‘minini’ character IP. Its blockchain-based ecosystem seeks to transparently record activities generated through interactions between IP and fans, including creation, consumption, and transactions, and link them to registration and settlement processes.

The minicoin payment service is planned for phased rollout across LINE FRIENDS stores in Korea and abroad, with a rollout targeted for the first half of 2027. The service is expected to offer international visitors and overseas fans additional payment options. K-POP SQUARE, which opened in the heart of Seoul’s Hongdae district in June 2025, welcomed over one million visitors in its first year, approximately 80% of whom were international fans from more than 90 countries. As digital assets gain traction as payment methods worldwide, the service is expected to see strong demand.

“This service rollout marks an important step toward using digital assets to purchase physical merchandise, beyond trading and use within specific platforms,” said an IPX official. “We believe that the value of IP can grow further as it expands beyond connecting with fans through content and products to finding new ways to engage with them across the digital IP ecosystem. We will continue to explore new IP business opportunities that connect IP, fans, and commerce together in this evolving landscape.”

 About IPX (F.K.A. LINE FRIENDS)

IPX is the new corporate name of LINE FRIENDS, a global character brand that started with original characters including BROWN, CONY, and SALLY, created for use as stickers for the leading mobile messenger app LINE and its 200 million active users worldwide. IPX has announced a new business strategy that it would accelerate the global expansion of its IP businesses by diversifying its IP portfolios targeting all ages and advancing its digital and retail business. IPX provides diverse IP experiences including BT21(BTS), ZO&FRIENDS(G-DRAGON), minini, and JOGUMAN. It has also carried out its IP-based business by partnering with global companies including Netflix (original animated series) and HoYoverse (Genshin Impact) to win the hearts of over 50 million Millennials and Generation Z worldwide. IPX currently operates in 18 markets worldwide, including Seoul, New York, LA, Tokyo, and Shanghai, and operates on 8 online sales platforms.

Contacts

Manager
Jiwoo Hong
Burson
jiwoo.hong@bursonglobal.com
Sr. Director
Hanna Park
Burson
hanna.park@bursonglobal.com